Transfar Zhilian (SZSE:002010) Will Be Hoping To Turn Its Returns On Capital Around

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. In light of that, when we looked at Transfar Zhilian (SZSE:002010) and its ROCE trend, we weren't exactly thrilled.

Advertisement

Return On Capital Employed (ROCE): What Is It?

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Transfar Zhilian:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.036 = CN¥1.1b ÷ (CN¥42b - CN¥13b) (Based on the trailing twelve months to September 2024).

So, Transfar Zhilian has an ROCE of 3.6%. In absolute terms, that's a low return and it also under-performs the Chemicals industry average of 5.5%.

Check out our latest analysis for Transfar Zhilian

roce
SZSE:002010 Return on Capital Employed February 8th 2025

Above you can see how the current ROCE for Transfar Zhilian compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for Transfar Zhilian .

How Are Returns Trending?

On the surface, the trend of ROCE at Transfar Zhilian doesn't inspire confidence. To be more specific, ROCE has fallen from 7.1% over the last five years. Given the business is employing more capital while revenue has slipped, this is a bit concerning. This could mean that the business is losing its competitive advantage or market share, because while more money is being put into ventures, it's actually producing a lower return - "less bang for their buck" per se.

In Conclusion...

We're a bit apprehensive about Transfar Zhilian because despite more capital being deployed in the business, returns on that capital and sales have both fallen. Long term shareholders who've owned the stock over the last five years have experienced a 17% depreciation in their investment, so it appears the market might not like these trends either. With underlying trends that aren't great in these areas, we'd consider looking elsewhere.

If you'd like to know more about Transfar Zhilian, we've spotted 4 warning signs, and 1 of them is a bit unpleasant.

While Transfar Zhilian isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Valuation is complex, but we're here to simplify it.

Discover if Transfar Zhilian might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SZSE:002010

Transfar Zhilian

Engages in the chemicals and logistics business in China and internationally.

Proven track record with adequate balance sheet.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5371.1% undervalued
32 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HE
PLY logo
HegelBayeBagel on PlaySide Studios ·

PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade

Fair Value:AU$0.8463.1% undervalued
7 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
AN
AnimalDoctorKwon
NOTV logo
AnimalDoctorKwon on Inotiv ·

Inotiv NAMs Test Center

Fair Value:US$1.275.7% undervalued
12 users have followed this narrative
2 users have commented on this narrative
4 users have liked this narrative
TH
CGNT logo
TheValueDetector on Cognyte Software ·

This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti

Fair Value:US$95.6792.6% undervalued
17 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

AG
Agricola
AUMB logo
Agricola on 1911 Gold ·

A case for TSXV:AUMB to reach USD$2.69 (CAD$3.70) by 2030 (15X).

Fair Value:CA$3.774.9% undervalued
19 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
composite32
FRU logo
composite32 on Freehold Royalties ·

Freehold: Offers a fantastic growth-income intersection up to $50 WTI. Below $50 WTI, it may offer historic opportunities in terms of ROI.

Fair Value:CA$19.3811.9% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
UN
unknown
GFI logo
unknown on Gold Fields ·

Beyond the "Value Trap"—Defending the $50 Intrinsic Floor

Fair Value:US$64.219.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.4% undervalued
59 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3638.3% undervalued
45 users have followed this narrative
19 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$603.2234.2% undervalued
1278 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative

Trending Discussion

Advertisement